Recent　progress　in　chimeric　antigen　receptor-modified　T-cell　(CAR-T　cell)　technology　in　cancer　therapy　is　extremely　promising,　especially　in　the　treatment　of　patients　with　B-cell　acute　lymphoblastic　leukemia.　In　contrast,　due　to　the　hostile　immunosuppressive　microenvironment　of　a　solid　tumor,　CAR　T-cell　accessibility　and　survival　continue　to　pose　a　considerable　challenge,　which　leads　to　their　limited　therapeutic　efficacy.　In　this　study,　we　constructed　two　anti-MUC1　CAR-T　cell　lines.　One　set　of　CAR-T　cells　contained　SM3　single　chain　variable　fragment　(scFv)　sequence　specifically　targeting　the　MUC1　antigen　and　co-expressing　interleukin　(IL)　12　(named　SM3-CAR).　The　other　CAR-T　cell　line　carried　the　SM3　scFv　sequence　modified　to　improve　its　binding　to　MUC1　antigen　(named　pSM3-CAR)　but　did　not　co-express　IL-12.　When　those　two　types　of　CAR-T　cells　were　injected　intratumorally　into　two　independent　metastatic　lesions　of　the　same　MUC1(+)　seminal　vesicle　cancer　patient　as　part　of　an　interventional　treatment　strategy,　the　initial　results　indicated　no　side-effects　of　the　MUC1　targeting　CAR-T　cell　approach,　and　patient　serum　cytokines　responses　were　positive.　Further　evaluation　showed　that　pSM3-CAR　effectively　caused　tumor　necrosis,　providing　new　options　for　improved　CAR-T　therapy　in　solid　tumors.